Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Standard of care updates in ovarian cancer: PARP inhibitors

Mansoor Mirza • 1 Oct 2019
ESMO 2019
Ovarian Cancer Bevacizumab Niraparib Olaparib Veliparib

Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, speaks on the landmark trials from ESMO 2019 regarding PARP inhibitors in ovarian cancer. These trials include PRIMA (NCT02655016), PAOLA-1 (NCT02477644) and AURELIA (NCT00976911), which evaluate concurrent and maintenance therapy of combination treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Mansoor Mirza

2:11
Long-term benefit from 1L maintenance PARP inhibitors in ovarian cancer
Mansoor Mirza • 29 Sep 2022
4:15
Optimal management of recurrent low grade endometrial cancer
Mansoor Mirza • 29 Sep 2022
2:20
ENGOT-EN1: carboplatin plus paclitaxel plus nintedanib for endometrial cancer
Mansoor Mirza • 24 Oct 2021
8:20
Immune checkpoint inhibitors for endometrial and cervical cancer
Mansoor Mirza • 24 Oct 2021

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
0:49
MITO-16a/MANGO-OV2a: plasma TF as a prognostic marker in ovarian cancer
Sergio Marchini • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals